Several landmark randomized clinical trials recently showed that rivaroxaban (RIV), a factor Xa (FXa) inhibitor, provides some clinical benefits that have not been observed with conventional anticoagulation regimens in patients with cardiovascular disease (Branch et al., 2019; Eikelboom et al., 2017; Mega et al., 2012). Here, F10 is linked to cardiovascular disorder.